阿法骨化醇与西那卡塞联合用药在血液透析继发性甲旁亢患者中的应用
Application of the Combination of Alfacalcidol and Cinacalcet in Patients with Secondary Hyperparathyroidism on Hemodialysis
王世明1
作者信息
- 1. 惠水县人民医院血透室,贵州黔南州 550600
- 折叠
摘要
目的 分析血液透析继发性甲旁亢患者应用阿法骨化醇与西那卡塞联合治疗的效果.方法 选取2021年10月—2023年10月惠水县人民医院收治的96例血液透析继发性甲旁亢患者为研究对象,以随机数表法分为对照组(48例,常规方案治疗)和观察组(48例,阿法骨化醇与西那卡塞联合治疗).分析两组患者甲状旁腺激素相关的血清指标及安全性.结果 治疗前,两组血钙、血磷以及全段甲状旁腺激素水平比较,差异无统计学意义(P均>0.05).治疗后,观察组血钙为(2.30±0.08)mmol/L高于对照组的(2.10±0.11)mmol/L,差异有统计学意义(t=4.253,P<0.05);观察组的血磷和全段甲状旁腺激素水平均低于对照组,差异有统计学意义(P均<0.05).治疗前后,两组的丙氨酸氨基转移酶以及天门冬氨酸氨基转移酶水平比较,差异无统计学意义(P均>0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论 血液透析继发性甲旁亢患者应用阿法骨化醇与西那卡塞治疗,可以调节血钙、血磷以及全段甲状旁腺激素水平,且不会对患者肝功能、肾功能造成影响,安全性较高.
Abstract
Objective To analyze the effect of hemodialysis patients with secondary hyperparathyroidism according to the combination of alfacalcitol and cinacalcet.Methods A total of 96 patients with secondary hyperparathyroidism on hemodialysis who were admitted to the Hemodialysis Unit of Huishui County People's Hospital were selected from Oc-tober 2021 to October 2023,and they were randomly sorted and divided into the control group(48 cases,treated with conventional protocols)and the observation group(48 cases,treated with alfacalcitol and cinacalcet).The serum in-dexes related to parathyroid hormone and safety were compared between the two groups.Results Comparing Blood cal-cium,blood phosphorus and the whole segment parathyroid hormone level before treatment between two groups,and the differences were not statistically significant(all P>0.05).After treatment,the blood calcium in the observation group was(2.30±0.08)mmol/L,which was higher than that of the control group(2.10±0.11)mmol/L,and the difference was statistically significant(t=4.253,P<0.05).The level of blood phosphorus and total parathyroid hormone in the ob-servation group were significantly lower than the observation group,and the differences were statistically significant(both P<0.05).Comparing alanine aminotransferase as well as aspartate aminotransferase levels before and after treat-ment between the two groups,and the differences were not statistically significant(all P>0.05).And the incidence of adverse reactions between the two groups were compered,and the difference was not statistically significant(P>0.05).Conclusion Hemodialysis patients with secondary hyperparathyroidism treated with alfacalcitol and cinacalcet can regulate the levels of blood calcium,blood phosphorus,and all-segment parathyroid hormone,and it will not affect the patients'liver function and renal function,with high safety.
关键词
阿法骨化醇/西那卡塞/血液透析/继发性甲旁亢Key words
Alfacalcitol/Cinacalcet/Hemodialysis/Secondary hyperparathyroidism引用本文复制引用
出版年
2024
NETL
NSTL
万方数据